CalAmp Announces Restructuring Plan, Will Reduce ~8% Of Workforce

CalAmp (NASDAQ:CAMP), a connected intelligence company that helps people and organizations improve operational performance, today announced that it initiated a restructuring plan to reduce approximately eight

CalAmp (NASDAQ:CAMP), a connected intelligence company that helps people and organizations improve operational performance, today announced that it initiated a restructuring plan to reduce approximately eight percent of its employees across various functions. The Company implemented these actions to realign its operations to be more consistent with its S&SS business model.

Total
0
Shares
Related Posts
Read More

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV